tradingkey.logo

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

ReutersMay 22, 2025 12:30 PM

- Quoin Pharmaceuticals Ltd 2EB0y.F:

  • QUOIN PHARMACEUTICALS ANNOUNCES FDA CLEARANCE TO INITIATE SECOND PIVOTAL WHOLE BODY QRX003 NETHERTON SYNDROME CLINICAL STUDY

  • QUOIN PHARMACEUTICALS LTD - EXPECTS TO COMPLETE RECRUITMENT BY Q1 2026 AND FILE NDA LATER IN YEAR

Further company coverage: [2EB0y.F]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI